Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer

Immunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patient...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2021-01, Vol.14, p.8293-8299
Main Authors: Wang, Xuning, Wang, Shixiang, Han, Yalin, Xu, Maolin, Li, Peng, Ke, Mu, Teng, Zhipeng, Huang, Pu, Diao, Ziyan, Yan, Yongfeng, Meng, Qingyu, Kuang, Yanshen, Zheng, Wei, Liu, Hongyi, Liu, Xuesong, Jia, Baoqing
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Cancer patients
Care and treatment
Clinical outcomes
Colorectal cancer
csmd1
Gastric cancer
Gene expression
Gene mutations
Genes
Genetic aspects
Genomes
Genomics
Immunotherapy
Mutation
Original Research
Patient outcomes
pdl1
Software
Stomach cancer
T cells
tumor mutation burden
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patients sensitive to immunotherapy was urgently needed. Public sequence data and corresponding clinical data were used to explore the potential biomarkers for immunotherapy. We found that is the most frequently mutated gene and its mutation is highly correlated with prognosis in gastric cancer patients. Interestingly, patients with mutated CSMD1 exhibit a high mutation burden and upregulated PDL1 expression. The ratio of microsatellite instability (MSI) in the CSMD1 mutation cohort was higher than that in the cohort without CSMD1 mutation. Furthermore, patients with CSMD1 mutation have been found to possess a higher number of activated CD4+ T cells and neoantigens. CSMD1 mutation may act as a novel biomarker for assessing the survival and immune therapy response in patients with gastric cancer.
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S325910